International Assets Investment Management LLC Has $3.60 Million Stake in Pfizer Inc. (NYSE:PFE)

International Assets Investment Management LLC trimmed its stake in Pfizer Inc. (NYSE:PFEGet Rating) by 2.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 75,570 shares of the biopharmaceutical company’s stock after selling 1,914 shares during the period. Pfizer comprises approximately 0.6% of International Assets Investment Management LLC’s investment portfolio, making the stock its 21st biggest position. International Assets Investment Management LLC’s holdings in Pfizer were worth $3,597,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. OLD Mission Capital LLC bought a new stake in Pfizer during the third quarter valued at $291,000. Morgan Stanley boosted its position in shares of Pfizer by 3.4% during the 2nd quarter. Morgan Stanley now owns 47,894,080 shares of the biopharmaceutical company’s stock worth $1,875,532,000 after purchasing an additional 1,582,052 shares in the last quarter. Venturi Wealth Management LLC boosted its position in shares of Pfizer by 1.1% during the 3rd quarter. Venturi Wealth Management LLC now owns 30,912 shares of the biopharmaceutical company’s stock worth $1,330,000 after purchasing an additional 338 shares in the last quarter. Center for Financial Planning Inc. boosted its position in shares of Pfizer by 1.9% during the 3rd quarter. Center for Financial Planning Inc. now owns 17,073 shares of the biopharmaceutical company’s stock worth $734,000 after purchasing an additional 313 shares in the last quarter. Finally, New World Advisors LLC bought a new position in shares of Pfizer during the 3rd quarter worth about $292,000. 66.50% of the stock is currently owned by institutional investors and hedge funds.

A number of equities analysts have recently issued reports on PFE shares. Citigroup increased their price objective on shares of Pfizer from $46.00 to $57.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 5th. Berenberg Bank set a $50.00 target price on shares of Pfizer in a report on Thursday, April 21st. Mizuho lowered their target price on shares of Pfizer from $56.00 to $55.00 in a report on Thursday, February 10th. The Goldman Sachs Group set a $51.00 target price on shares of Pfizer in a report on Wednesday, May 4th. Finally, StockNews.com upgraded shares of Pfizer from a “buy” rating to a “strong-buy” rating in a report on Tuesday, April 19th. Eleven analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Buy” and a consensus target price of $57.05.

In other news, EVP William R. Carapezzi, Jr. sold 32,908 shares of the firm’s stock in a transaction that occurred on Thursday, May 12th. The shares were sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the completion of the sale, the executive vice president now owns 38,146 shares in the company, valued at approximately $1,907,300. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.05% of the company’s stock.

NYSE:PFE traded down $0.47 on Friday, hitting $49.92. The stock had a trading volume of 22,423,685 shares, compared to its average volume of 24,886,970. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.19 and a current ratio of 1.40. The stock has a market cap of $281.94 billion, a P/E ratio of 11.45, a price-to-earnings-growth ratio of 0.59 and a beta of 0.76. Pfizer Inc. has a 1 year low of $38.47 and a 1 year high of $61.71. The firm’s fifty day simple moving average is $51.27 and its two-hundred day simple moving average is $51.84.

Pfizer (NYSE:PFEGet Rating) last issued its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.80 by ($0.18). Pfizer had a return on equity of 39.33% and a net margin of 26.97%. The company had revenue of $25.66 billion for the quarter, compared to analysts’ expectations of $24.73 billion. During the same quarter in the previous year, the business earned $0.93 EPS. The company’s revenue for the quarter was up 76.8% on a year-over-year basis. Equities research analysts predict that Pfizer Inc. will post 6.69 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 10th. Stockholders of record on Friday, May 13th will be paid a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, May 12th. This represents a $1.60 annualized dividend and a dividend yield of 3.21%. Pfizer’s payout ratio is currently 36.70%.

Pfizer Profile (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Recommended Stories

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.